About Immedica
Immedica is a company based in Stockholm (Sweden) founded in 2017 was acquired by KKR in April 2024. Immedica has completed 2 acquisitions, including Marinus Pharma and Neurocrine. Immedica operates in a competitive market with competitors including AmerisourceBergen, Daiichi Sankyo, Beactica, Asgard Therapeutics and Alligator Bioscience, among others.
- Headquarter Stockholm, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
KKR
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
Marinus Pharma
& 1 more
-
Acquired by
KKR
(Apr 23, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Immedica
Unlock access to complete
Funding Insights of Immedica
Detailed funding history for Immedica
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Immedica
Immedica has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include KKR and Impilo.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Locked | Locked | Locked | |
|
Impilo is focused on healthcare investments in Nordic regions.
|
Locked | Locked | Locked |
Investor details for Immedica
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immedica
Immedica has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Marinus Pharma and Neurocrine.
Investment portfolio details for Immedica
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of therapeutics to treat seizure disorders
|
Locked | Locked | 2003 | Locked | |
|
Developer of small molecule therapeutics for endocrine and CNS disorders
|
Locked | Locked | 1992 | Locked |
Complete acquisition details for Immedica
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Immedica
Detailed financials for Immedica
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immedica Comparisons
Peer comparison for Immedica
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immedica
Immedica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AmerisourceBergen, Daiichi Sankyo, Beactica, Asgard Therapeutics and Alligator Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical distribution and supply chain services are provided globally.
|
|
| Locked | Locked | Locked |
Pharmaceutical drugs are developed to address diverse medical needs.
|
|
| Locked | Locked | Locked |
Develops small molecule drugs for oncology
|
|
| Locked | Locked | Locked |
Cancer immunotherapies are developed via direct cell reprogramming techniques.
|
|
| Locked | Locked | Locked |
Alligator Bioscience is focused on tumor-directed cancer immunotherapy development.
|
|
| Locked | Locked | Locked |
Personalized immunotherapeutics are developed for oncology and autoimmune diseases.
|
Detailed competitors of Immedica
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immedica
Complete news archive for Immedica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immedica
Immedica was founded in 2017.
Immedica is headquartered in Stockholm, Sweden.
Anders Edvell is the current CEO of Immedica.
Immedica was founded in 2017 in Stockholm, Sweden, as a developer of therapeutic agents targeting oncology, neurology, infectious diseases, ophthalmology, and inflammatory conditions. Drugs such as Arlevert and Vertisan have been created for vertigo treatment across various origins, while additional agents address corneal neovascularization. Operations focus on pharmaceutical innovation within these medical sectors.
Immedica's top competitors include AmerisourceBergen, Daiichi Sankyo and Alligator Bioscience.
Immedica has made 2 acquisitions, including Marinus Pharma, and Neurocrine.